NASDAQ · NBP
Healthcare · Biotechnology
$1.87
Up+$0.03 (+1.60%)
Updated Aug 13, 2026, 10:04 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NBP closed at $1.87 after 21 trading sessions, up 1.08% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.85 | $1.88 | $1.80 | $1.87 | 217.01K |
| Aug 11, 2026 | $1.78 | $1.85 | $1.761 | $1.84 | 318.92K |
| Aug 10, 2026 | $1.75 | $1.836 | $1.74 | $1.77 | 254.22K |
| Aug 7, 2026 | $1.70 | $1.77 | $1.70 | $1.75 | 178.26K |
| Aug 6, 2026 | $1.66 | $1.74 | $1.64 | $1.70 | 156.52K |
| Aug 5, 2026 | $1.65 | $1.66 | $1.60 | $1.64 | 152.86K |
| Aug 4, 2026 | $1.60 | $1.675 | $1.60 | $1.65 | 250.21K |
| Aug 3, 2026 | $1.63 | $1.63 | $1.585 | $1.61 | 168.58K |
| Jul 31, 2026 | $1.65 | $1.65 | $1.58 | $1.60 | 169.2K |
| Jul 30, 2026 | $1.63 | $1.65 | $1.58 | $1.64 | 253K |
| Jul 29, 2026 | $1.75 | $1.765 | $1.61 | $1.61 | 296.6K |
| Jul 28, 2026 | $1.77 | $1.77 | $1.71 | $1.75 | 247.69K |
| Jul 27, 2026 | $1.77 | $1.87 | $1.7658 | $1.78 | 175.04K |
| Jul 24, 2026 | $1.77 | $1.78 | $1.70 | $1.77 | 199.41K |
| Jul 23, 2026 | $1.74 | $1.78 | $1.72 | $1.77 | 414.65K |
| Jul 22, 2026 | $1.82 | $1.82 | $1.715 | $1.74 | 354.87K |
| Jul 21, 2026 | $1.81 | $1.84 | $1.735 | $1.83 | 265.57K |
| Jul 20, 2026 | $1.79 | $1.90 | $1.78 | $1.79 | 282.13K |
| Jul 17, 2026 | $1.76 | $1.83 | $1.74 | $1.78 | 217.42K |
| Jul 16, 2026 | $1.83 | $1.86 | $1.765 | $1.79 | 263.94K |
| Jul 15, 2026 | $1.85 | $1.8698 | $1.79 | $1.85 | 249.69K |
The latest Smart Investors Daily articles mentioning NBP.
NBP research
Company profile and research snapshot.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 8, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 6, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jun 16, 2026
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge
Yahoo · Feb 19, 2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge subsidiary company Visara, Inc., will also join the Board
Benzinga · Feb 19, 2026
Yahoo · Feb 17, 2026
Global, randomized Phase 2 study to evaluate the addition of givastomig, a CLDN18.2 x 4-1BB bispecific antibody (8 mg/kg and 12 mg/kg) to standard of care immunochemotherapy in patients with first line (1L) metastatic gastric cancerMajor milestone builds on positive Phase 1b combination data demonstrating that givastomig produced, best-in-class potential efficacy in 1L HER2-negative, metastatic gastric cancer patients in combination with nivolumab and chemotherapy (mFOLFOX6)Phase 1b results show
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NBP.
